Biostax (BTAX) 10-K/A 28 Aug 20 2019 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Aug. 24, 2020	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	0001559356
Document Type	10-K/A
Document Period End Date	Dec. 31, 2019
Amendment Flag	true
Amendment Description	Immune Therapeutics, Inc. (the "Company") is filing this Amendment No. 1 on Form 10-K/A (this "Form 10-K/A") to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the "Original Form 10-K"), as filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2020. The purposes of this Form 10-K/A are to (i) refile a revised Signature page to comply with instruction D(2)(a) of the General Instructions to Form 10-K, and (ii) file the certification of Peter Aronstam, the Company's Chief Financial Officer, required pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as Exhibit 32.2 to this Form 10-K/A, which was inadvertently omitted from the Original Form 10-K. In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, as a result of this Form 10-K/A, the Company is refiling the certifications of Kevin Phelps, the Company's Chief Executive Officer, and Peter Aronstam, the Company's Chief Financial Officer, required pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002, as Exhibits 31.1, 31.2, and 32.1 to this Form 10-K/A. Except as described above, and in Note 14. "Subsequent Events" of the footnotes to the Consolidated Financial Statements, no other changes have been made to the Original Form 10-K, and this Form 10-K/A does not modify or update any other disclosures made in the Original Form 10-K. Furthermore, this Form 10-K/A does not change any previously reported financial results. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the Original Form 10-K was filed. Accordingly, this Form 10-K/A should be read in conjunction with the Original Form 10-K and the Company's other filings with the SEC subsequent to the filing of the Original Form 10-K.
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 13,372,401
Entity Common Stock, Shares Outstanding		457,578
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 4,925	$ 5,859
Inventories		82,801
Total current assets	4,925	88,660
Fixed Assets:
Computer equipment, net of accumulated depreciation of $12,522 and $10,447 respectively	691	2,766
Deposits	200	200
Total assets	5,816	91,626
Current Liabilities:
Accounts payable	2,655,949	2,065,476
Accrued liabilities	4,694,988	3,039,710
Net payables due to Cytocom		262,645
Notes payable, net of debt discount	5,545,371	5,187,727
Derivative liability	798,126	786,706
Total current liabilities	13,694,437	11,342,264
Total liabilities	13,694,437	11,342,264
Stockholders' Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 457,578 and 434,323 shares issued and outstanding respectively	46	44
Additional paid in capital	370,908,099	369,924,426
Stock issuances due	10,303	35,303
Accumulated deficit	(384,607,069)	(381,210,411)
Total stockholders' deficit	(13,688,621)	(11,250,638)
Total liabilities and stockholders' deficit	$ 5,816	$ 91,626

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 12,522	$ 10,447
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	457,578	434,323
Common stock, shares outstanding	457,578	434,323

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues, net		$ 113,500
Cost of products sold		47,673
Gross profit		65,827
Operating expenses:
Selling, general and administrative	2,368,474	3,232,323
Research and development expense	336,110	144,099
Stock issued for services general and administrative	131,390	772,495
Depreciation and amortization expense	2,074	1,733
Total operating expenses	2,838,048	4,150,650
Loss from operations	(2,838,048)	(4,084,823)
Other expense:
Interest expense	(894,173)	(1,183,196)
Loss (Gain) on valuation of derivative	(46,745)	494,445
Loss on settlement of debt		(684,768)
Recovery of amount due from Cytocom	382,308
Loss on deconsolidation		(2,791,172)
Loss from equity method investment		(376,196)
Total other expense	(558,610)	(4,540,887)
Net loss	(3,396,658)	(8,625,710)
Net loss attributable to non-controlling interest		(450,382)
Net loss attributable to common stockholders	$ (3,396,658)	$ (8,175,228)
Basic loss per share attributed to common stockholders	$ (8.44)	$ (19.03)
Weighted average number of shares outstanding	447,530	429,662

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock To Be Issued [Member]	Prepaid Services [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2017	$ 39	$ 366,663,784	$ 103,226	$ (226,667)	$ (373,035,183)	$ (4,608,585)	$ (11,103,386)
Balance, shares at Dec. 31, 2017	386,782
Issuance of common stock for services	$ 2	613,749	(67,923)				545,828
Issuance of common stock for services, shares	16,989
Amortization of prepaid services				226,667			226,667
Issuance of common stock for interest expense	$ 1	9,100					9,101
Issuance of common stock for interest expense, shares	200
Issuance of common stock in exchange for debt	$ 3	671,584					671,587
Issuance of common stock in exchange for debt, shares	30,351
Issuance of Cytocom common stock for cash and exercise of warrants		240,500					240,500
Issuance and modification of common stock warrants		1,725,708					1,725,708
Deconsolidation of Cytocom						5,058,967	5,058,967
Net loss					(8,175,228)	(450,382)	(8,625,710)
Balance at Dec. 31, 2018	$ 44	369,924,426	35,303		(381,210,411)		(11,250,638)
Balance, shares at Dec. 31, 2018	434,323
Issuance of common stock for services		145,000	(25,000)				120,000
Issuance of common stock for services, shares	3,000
Amortization of prepaid services							0
Issuance of common stock in exchange for debt	$ 2	62,433					62,435
Issuance of common stock in exchange for debt, shares	18,255
Issuance of warrants in connection with debt agreement		73,000					73,000
Issuance of common stock to board members		11,390					11,390
Issuance of common stock to board members, shares	2,000
Extinguishment of debt assumed by related party		691,850					691,850
Net loss					(3,396,658)		(3,396,658)
Balance at Dec. 31, 2019	$ 46	$ 370,908,099	$ 10,303		$ (384,607,069)		$ (13,688,621)
Balance, shares at Dec. 31, 2019	457,578

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss including non-controlling interest	$ (3,396,658)	$ (8,625,710)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	2,074	1,734
Stock issued for services	131,390	710,150
Amortization of stock issued for prepaid services		226,667
Loss (Gain) on derivative	46,745	(494,445)
Loss on settlement of debt and accounts payable		684,768
Interest accrued on debt	26,019
Stock issued for loan expenses and interest		9,000
Loss on deconsolidation		2,791,172
Loss on equity method		376,196
Recovery of amount due from Cytocom	(382,308)
Amortization of debt discount	222,257	420,747
Expenses paid by lenders		305,005
Penalties related to note default		90,123
Changes in operating assets and liabilities:
Inventory	82,801	95,297
Accrued liabilities	2,252,127	1,698,231
Due to Cytocom	119,668
Accounts payable	894,951	341,562
Net cash used in operating activities	(934)	(1,369,503)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment		(1,971)
Net cash used in investing activities		(1,971)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock		240,500
Proceeds from notes payable		859,470
Due from Cytocom		(152,355)
Due to Cytocom		415,000
Repayment of notes payable
Net cash provided by financing activities		1,362,615
Decrease in cash	(934)	(8,859)
Cash and cash equivalents, beginning of year	5,859	14,718
Cash and cash equivalents, end of year	4,925	5,859
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	16,000	59,551
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable, accrued liabilities and accounts payable to common stock	27,110	792,574
Debt settled and reclassed to accrued expenses	35,325	243,199
Reclassification from accounts payable to notes payable	304,478
Notes Payable and accrued interest assumed by related party	691,850
Debt discounts on notes payable and warrants	73,000	243,000
Transfer from accounts payable to notes payable		345,321
Notes payable for expenses paid by lender		150,505
Non-cash additions to notes payable		$ 538,123

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company,” “we,” or “our”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc. The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally. In December 2013, the Company formed a subsidiary, Cytocom Inc. (“Cytocom”), to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom to its shareholders. As part of the transaction (“Original Agreement”), the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On December 8, 2014, the number of Cytocom shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the Original Agreement, Cytocom issued an additional 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% stake in Cytocom on that date. In April 2016, the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement. Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis. The Restated Agreement was a condition of the Stock Agreement. On April 8, 2019, the Company signed a second amendment to its licensing agreement (the “Second Amendment” with Cytocom. The Second Amendment confirmed that, as of its effective date (December 31, 2018) the Company owned 15.57% of the common shares issued and outstanding on that date. The Company agreed to assume the obligation to repay all accounts payable obligations and accrued liabilities owed by Cytocom as of the effective date, except those accounts’ payable obligations and accrued liabilities as specified in the Second Amendment. The Company also assumed the obligation to repay all notes payable, together with any interest or fees payable thereon, owed by Cytocom as of the effective date, except those notes’ payable obligations, together with any interest or fees payable thereon, as specified by the Second Amendment. The parties further agreed that in the event of a change of control of Cytocom, and at the option of Cytocom, the Company would have the right to purchase outright the Company’s licensing rights to Emerging Markets for humans under the License Agreement at a price equal to value of those licensing rights as determined by and independent valuator acceptable to the Company and Cytocom. At December 31, 2019, the Company’s equity interest in Cytocom stood at 14.6% of Cytocom’s issued and outstanding common stock. The Company’s policies with respect to accounting for its equity interest in Cytocom is described in Note 2 to the “Notes to the Condensed Consolidated Financial Statements” below (“Summary of Significant Accounting Policies: Non-Controlling Interest in Consolidated Subsidiaries”). At present, the Company is a late development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for humans in Africa, Central and South America, the Caribbean and China (hereinafter referred to as “Emerging Markets”) and worldwide for animals and companion pet therapeutics. As the Company does not FDA approval, it is not permitted to market its licensed products in the United States. Going Concern The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at December 31, 2019 was not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. The Company experienced a net loss attributable to common shareholders of $3,396,658 and used cash and cash equivalents for operations in the amount of $934 during the year ended December 31, 2019, and had a stockholders’ deficit of $13,688,621 at December 31, 2019.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2018. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At December 31, 2019, the Company’s equity interest in Cytocom stood at 14.6% of Cytocom’s common stock issued and outstanding. The Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. As the balance of the Company’s investment in Cytocom has been $0 since December 31, 2018, no losses have been recognized during the year ended December 31, 2019. Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. Sales of Lodonal TM Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. At December 31, 2019 we had no leases to which the standard applies. Accordingly, the standard had no material impact on our results of operations in 2019. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2019, the Company has no cash balances in excess of insured limits. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Derivative Financial Instruments FASB ASC 815, Fair Value Measurements Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense. Inventory as of December 31, 2019 was valued at $0, a decrease of $82,801 or 100% from the inventory balance at the end of 2018, as the inventory was deemed obsolete during June of 2019, and written off as a component of selling, general and administrative expense. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the years ended December 31, 2019 and December 31, 2018 was $2,074 and $1,733, respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2019 and 2018, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2019, and 2018, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The Company’s potential dilutive securities, which include stock and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2019 2018 Common Stock Purchase Warrants 4,187,579 281,251 Convertible Debt 168,160 180,603 Recent Accounting Standards During the year ended December 31, 2019, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2019
Fixed Assets:
Fixed Assets	3. Fixed Assets December 31, 2019 2018 Fixed assets: Computer equipment $ 13,213 $ 13,213 Less accumulated depreciation (12,522 ) (10,447 ) Fixed assets, net $ 691 $ 2,766 The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

Investments_ Deconsolidation of

Investments: Deconsolidation of Cytocom	12 Months Ended
	Dec. 31, 2019
Investments Deconsolidation Of Cytocom
Investments: Deconsolidation of Cytocom	4. Investments: Deconsolidation of Cytocom In accordance with the May 1, 2018 “Restated Agreement” with Cytocom, the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. Accordingly, effective May 1, 2018, the Company deconsolidated Cytocom. However, the Company exercises influence through its retained equity interest and through representation on Cytocom’s board of directors. As a result, the Company uses the equity method to account for its retained interest in Cytocom. While the Company formalized the agreement to deconsolidate on May 1, 2018, Cato Research Ltd and Penn State University, both vendors of the Company, did not consent to assign the payables to Cytocom. As such, on December 31, 2019, the Company had outstanding accounts payable balances of $409,390 and $377,774 due to Cato Research Ltd and Penn State University, respectively. Additionally, the Company reached a settlement with Cytocom to recover the net payable balance outstanding of $382,308 at December 31, 2019. The Company recorded a gain on the settlement of that amount. On May 1, 2018, the Company recorded an equity method investment in Cytocom of $1,189, the par value of Cytocom common stock multiplied by the number of shares owned by the Company, due to the negative equity associated with Cytocom’s underlying financial position. As a result of the continuing losses in Cytocom, the balance of this investment is currently $0.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Liabilities	5. Accrued Liabilities Accrued expenses and other liabilities consist of the following: December 31, 2019 2018 Accrued payroll to officers and others 3,610,810 2,010,570 Accrued interest and penalties - notes payable 899,904 877,571 Estimated legal settlements 136,057 136,057 Other accrued liabilities 48,217 15,512 Total accrued expenses and other liabilities $ 4,694,988 $ 3,039,710

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable Notes payable consist of the following: December 31, 2019 December 31, 2018 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. The note earned interest at a rate of 18% per annum. The Company settled this note with a new note in the same amount on October 1, 2019. $ - $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at December 31, 2019, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $675,994 earn interest at rates between 2% and 10% per annum. One loan, in the amount of $100,000, interest was payable in a fixed amount not tied to a specific interest rate. However, this note was extinguished and reassigned to a related party during the year ended December 31, 2019. The Company was unable to repay the remaining notes at maturity and at December 31, 2019 these notes were in default. 625,994 725,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at December 31, 2019 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at December 31, 2019 the notes were in default. 206,000 206,000 Promissory notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As December 31, 2019, the notes were in default. 1,354,000 1,354,000 Promissory notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and September 30, 2018. At December 31, 2019, the notes were in default. 500,000 500,000 Promissory notes issued January 25, 2017. The lenders earn interest at 7% per month. The notes matured on July 5, 2017, and at December 31, 2019 the notes were in default. The Company settled this note with a new note in the same amount on October 1, 2019. - 50,000 Promissory notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At December 31, 2019, the notes were in default. 300,000 300,000 Promissory notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At December 31, 2019, the notes were in default. 191,800 191,800 Promissory note for $425,000 issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at December 31, 2019 had increased to $454,032. $49,943 of accrued interest owed on the note has been converted to stock. The Company has accrued a $798,126 derivative liability for the remaining conversion right. 454,032 455,122 Promissory notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At December 31, 2019, the notes were in default. 105,500 105,500 Promissory notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At December 31, 2019, the notes were in default. 47,975 47,975 Promissory notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000 and 20,000 shares with an exercise price of $0.5. At December 31, 2019 the notes were in default 125,000 125,000 Promissory notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000 and 5,000 shares with an exercise price of $5. At December 31, 2019 the notes were in default 65,000 65,000 Promissory notes aggregating $198,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600 and 5,000 shares with an exercise price of $5. At December 31, 2019, the notes were in default. 198,000 193,000 Promissory notes aggregating $533,855 issued in the fourth quarter of 2018. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200 and 39,500 shares with an exercise price of $5 to $40. At December 31, 2019, the note was in default. 533,855 533,855 Promissory note for $23,000 issued in the first quarter of 2019. The note accrues interest at 2% per annum and matures during July 2019. The note includes warrants for 4,600 shares with an exercise price of $5. At December 31, 2019, the note was in default. 23,000 - Promissory note for $231,478 issued in the first quarter of 2019. The note accrues interest at 6% per annum and matured in February 2020. As of the date of this filing, this note is in default. 231,478 - Promissory notes aggregating $50,000 issued in the second quarter of 2019. The notes accrue interest at 2% per annum and mature between July and September 2019. These notes include warrants for 10,000 shares with an exercise price of $5. At December 31, 2019, the notes were in default. 50,000 - Promissory note in the amount of $150,000 issued on October 1, 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15% per annum, with $1,875 due in monthly interest payments. and matures on April 30, 2021. 150,000 - Less: Original issue discount on notes payable and warrants issued with notes. - (149,256 ) Total $ 5,545,371 $ 5,187,727 As of December 31, 2019, the Company had accrued $899,904 in unpaid interest and default penalties. During the year ended December 31, 2019, 18,255 shares with a fair value of $78,500 were issued by the Company for settlement of promissory notes totaling $62,435. As of December 31, 2018, the Company had accrued $877,571 in unpaid interest and default penalties. During the year ended December 31, 2018, 30,351 shares with a fair value of $318,182 were issued by the Company for settlement of promissory notes totaling $175,000. The Company settled a note of $100,000 with accrued interest and penalties in the amount of $596,850 during the yearend December 31, 2019, by assigning them to a related party. In accordance with ASC 470-50-40-2, the extinguishment transactions between related entities may be in essence capital transactions. Therefore, when related parties are involved, recognition of the difference between the retired debt’s reacquisition price and carrying amount as either a gain or loss may not be appropriate. As such, no gain on the extinguishment of the transaction was recorded.

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	7. Derivative Liability As of December 31, 2019, and December 31, 2018, the fair value of the outstanding derivative liability was $798,126 and $786,706 respectively. The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumptions during the year ended December 31, 2019: Year End Volatility 165.62 % Risk-free interest rate 1.96 % Expected dividends - % Expected term 1 year The Company determines the fair market values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses Level 3 inputs to estimate the fair value of its derivative liabilities. The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of December 31, 2019: Fair Value Measurements as of Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability - - 798,126 Total liabilities $ - $ - $ 798,126 The following table sets forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Beginning balance $ 786,706 Settlement of liability - Change in fair value 46,745 Partial settlements of liability (35,325 ) Ending balance $ 798,126

Capital Structure - Common Stoc

Capital Structure - Common Stock and Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Capital Structure - Common Stock and Common Stock Purchase Warrants	8. Capital Structure—Common Stock and Common Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of December 31, 2019, and 2018, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. As of December 31, 2019, the Company had 457,578 shares of common stock outstanding and 434,323 outstanding as of December 31, 2018. Stock Warrants In 2019, the Company issued 14,600 warrants upon the issuance of debt, exercisable into one share of common stock of the Company for each warrant at prices of $5.00 per share. The warrants expire between March and May of 2024. When the Company sells its stock to stockholders for cash, it periodically issues warrants to those stockholders to acquire additional stock at prices agreed at the date of the original sale. The Company incurs a cost for the rights attached to the warrants, which is calculated using the Black-Scholes Model. This expense is reported in the Statements of Operations above as the Warrant valuation expense. During 2019, there were no modifications of the terms of any warrants issued by the Company. Following is a summary of outstanding stock warrants at December 31, 2019: Number of Exercise Per Share Weighted Warrants as of December 31, 2017 84,287 $ 10-15,000 $ 330 Issued in 2018 4,122,833 $ 10-3,740 $ 110 Expired and forfeited in 2018 6,500 $ 15,000 $ 1,450 Exercised in 2018 - $ - $ - Warrants as of December 31, 2018 4,200,620 $ 0.05-3,740 $ 90 Issued in 2019 14,600 $ 5 $ 5 Expired and forfeited in 2019 27,641 $ 50-3,740 $ 536 Exercised in 2019 - $ - $ - Warrants as of December 31, 2019 4,187,579 $ 0.05-500 $ 2.43 Summary of outstanding warrants as of December 31, 2019: Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2020 300 $ 500 0.50 Fourth Quarter 2020 1,000 $ 200 1.00 First Quarter 2021 12,600 $ 200 1.25 Second Quarter 2021 5,812 $ 14-200 1.50 Third Quarter 2021 5,167 $ 30-200 1.75 Fourth Quarter 2021 300 $ 100 2.00 First Quarter 2022 150 $ 200 2.25 Second Quarter 2022 1,750 $ 150 2.50 Third Quarter 2022 2,650 $ 50-100 2.75 Fourth Quarter 2022 9,811 $ 80-290 3.00 First Quarter 2023 9,000 $ 5-40 3.25 Second Quarter 2023 15,000 $ 5-200 3.50 Third Quarter 2023 76,700 $ 5-100 3.75 Fourth Quarter 2023 3,970,743 $ 0.05-20 4.00 First Quarter 2024 36,600 $ 5 4.25 Second Quarter 2024 8,000 $ 5 4.50 Third Quarter 2028 3,000 $ 70 8.75 Second Quarter 2032 28,995 $ 10-70 12.50 4,187,579 $ 0.05-500

Stock Compensation

Stock Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Compensation	9. Stock Compensation Shares Issued for Services During the years ended December 31, 2019 and 2018, the Company issued 0 and 16,999 shares of common stock respectively for consulting fees. The Company valued these shares based upon the fair value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled 0 and $226,667 for the years ended December 31, 2019 and 2018, respectively.

Income Taxes - Results of Opera

Income Taxes - Results of Operations	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes - Results of Operations	10. Income Taxes - Results of Operations There was no income tax expense reflected in the results of operations for the years ended December 31, 2019 and 2018 because the Company incurred a net loss in both years. On December 22, 2018, the President of the United States signed the Tax Cuts and Jobs Act (“U.S. Tax Reform”), which enacts a wide range of changes to the U.S. corporate income tax system. The impact of U.S. Tax Reform primarily represents the Company’s estimates of revaluing the Company’s U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%, effective for the 2018 tax year. Based on the Company’s historical financial performance, at December 31, 2018, the net deferred tax asset position was re-measured at the lower corporate rate of 21% and a tax expense was recognized to adjust net deferred tax assets to the reduced value. Deferred tax assets: 2019 2018 Net operating losses $ 20,346,000 $ 19,671,000 Stock based compensation 39,284,000 39,256,000 Amortization, depreciation, and impairment 4,178,000 4,178,000 Capitalization of start-up costs for tax purposes 1,145,000 1,145,000 Gain/(loss) on conversion of debt 713,000 713,000 Total deferred tax assets 65,666,000 64,963,000 Valuation allowance (65,666,000 ) (64,963,000 ) Total deferred tax assets, net $ - $ - The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2019. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. As of December 31, 2019, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $97,069,000, which will expire in 2032-2037. 2019 2018 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ 713,000 21 % $ 1,811,000 21 % Permanent differences 10,000 (2,000 ) Increase (decrease) in valuation allowance (703,000 ) (21) % (1,809,000 ) (21) % Income tax expense (benefit) at Company’s effective tax rate $ - - % $ - - %

Licenses and Supply Agreements

Licenses and Supply Agreements	12 Months Ended
	Dec. 31, 2019
Licenses And Supply Agreements
Licenses and Supply Agreements	11. Licenses and Supply Agreements Patent License Agreements In December 2014, the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. Cytocom licensed back to the Company a perpetual, non-exclusive, royalty-free right and license to use the assigned intellectual property for veterinary indications and for the marketing rights to emerging markets, access to all clinical data, use of the formulation for LDN and MENK. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. In addition, the Company has been granted the rights to distribute and market Lodonal™ and MENK for animal use in the United States. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for the cost in connection with the assets of Cytocom.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Distribution Agreements in Nigeria In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The first deliveries under the agreement took place in February 2018. Under the original agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment. Due to the fact that AHAR Pharma failed to meet its contractual purchase obligations, the Company formally issued notice of default under the agreement. On April 18, 2018, AHAR Pharma transferred its rights under the Distribution Agreement to Fidson Healthcare Plc (“Fidson”), and Fidson signed an exclusive distribution agreement with the Company to distribute Lodonal™. There were no shipments under this agreement during the year ended December 31, 2019. There were also no discussions with Fidson regarding the Distribution Agreement in 2019. Contract Manufacturing Agreements On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”), which is based in the Dominican Republic, entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms. Operating Leases At December 31, 2019, the Company was a party to an agreement to a short-term lease office space in Orlando, Florida. Rental expense for the years ended December 31, 2019 and 2018 was $12,661 and $11,775 respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions Michael Handley, the Company’s Chief Executive Officer until May 1, 2020, was entitled to receive compensation of $120,000 for the year ended December 31, 2019. Mr. Handley has unpaid cash compensation of $120,000, at December 31, 2019, which is included in accrued expenses. Noreen Griffin, the Company’s former Chief Executive Officer, was entitled to receive compensation of $377,960 and $355,594, respectively, for the years ended December 31, 2019 and 2018. Mrs. Griffin has unpaid cash compensation of $1,962,464 and $1,584,504, at December 31, 2019 and 2018, respectively, which is included in accrued expenses. There was an additional $48,217 due to Mrs. Griffin at December 31, 2019. Robert Wilson, the son of Noreen Griffin, the Company’s former Chief Executive Officer, is employed by the Company. Mr. Wilson was entitled to receive compensation of $120,000 for each of the years ended December 31, 2019 and 2018. No cash compensation was paid to Mr. Wilson in 2019 (in 2018, he received payments totaling $70,000). Mr. Wilson has unpaid cash compensation of $190,000 and $70,000, at December 31, 2019 and 2018, respectively, which is included in accrued expenses. In 2018, Mr. Wilson received 500,000 stock options, with a fair value of $24,998. Kelly O’Brien Wilson, the daughter-in-law of Noreen Griffin, the Company’s former Chief Executive Officer, is employed by the Company. Ms. Wilson was entitled to receive compensation of $163,390 for each of the years ended December 31, 2019 and 2018. No cash compensation was paid to Ms. Wilson in 2019 (in 2018, she received payments totaling $136,158). Ms. Wilson has unpaid cash compensation of $258,701 and $95,311, at December 31, 2019 and 2018, respectively, which is included in accrued expenses. In 2018, Ms. Wilson received 1,200,000 stock options, with a fair value of $59,995. Peter Aronstam, the Company’s Chief Financial Officer, was entitled to receive compensation of $60,000 for the years ended December 31, 2019 and 2018. Mr. Aronstam has unpaid cash compensation of $71,000 and $36,000, at December 31, 2019 and 2018, respectively, which is included in accounts payable. Dr. Clifford Selsky, who served on the board of directors until May 4, 2020, was entitled to receive compensation of $5,000 a month. Dr. Selsky has unpaid cash compensation of $230,000 and $60,000, at December 31, 2019 and 2018, respectively, which is included in accounts payable. Kevin Phelps, who serves on the board of directors, is entitled to receive compensation of $5,000 a month. Mr. Phelps has unpaid cash compensation of $65,000 and $10,000 at December 31, 2019 and 2018, respectively, which is included in accounts payable. Michael Sander, who serves on the board of directors, is entitled to receive compensation of $5,000 a month. Mr. Sander has unpaid cash compensation of $10,000 and $0, at December 31, 2019 and 2018, respectively, which is included in accounts payable. In 2019, Dr. Roscoe Moore, the chairman of the board of directors, also served as a senior advisor to the Company under an Independent Senior Advisor Agreement. As compensation for his services in that role, Dr. Moore is to be paid a monthly fee of $1,500. During the year ended December 31, 2018, Moore also received 1,875,000 shares of common stock for these services (with a fair value of $37,500). Dr. Moore had accrued compensation of $95,250 and $24,500 at December 31, 2019 and 2018, which is included in accounts payable. Dr. Moore had a note payable with a balance of $25,000 at December 31, 2019. Edward Teraskiewicz, who served on the board of directors until October 31, 2019, was entitled to receive compensation of $5,000 a month. Mr. Teraskiewicz has unpaid cash compensation of $114,643 and $45,000, at December 31, 2019 and 2018, respectively, which is included in accounts payable. Jack Brewer, who served on the board of directors, was entitled to receive compensation of $5,000 a month. Mr. Brewer has unpaid cash compensation of $60,000 and $20,000, at December 31, 2019 and 2018, respectively, which is included in accounts payable. At December 31, 2019 and 2018, the Company had a payable of $36,000, to Brewer and Associates Consulting LLC, a consulting firm owned by Jack Brewer, for services rendered in prior periods. In 2019, the Company issued a note payable for $40,000 to Raster Investments, Inc. a trust related to Edward Teraskiewicz. The notes bear interest at a rate of 2% per annum. In 2018, the Company issued two notes payable aggregating $210,000 to Raster Investments, Inc. for services performed by Mr. Teraskiewicz for the Company ($150,000) in 2018 and to repay other liabilities ($60,000). The notes bear interest at a rate of 2% per annum and as of December 31, 2019, was in default. In 2019, the Company issued a note payable for $23,000 to Global Reverb, Corp. a company on which Noreen Griffin serves as a director. The notes bear interest at a rate of 2% per annum and as of December 31, 2019, was in default.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Between January 1, 2020 and May 14, 2020, the Company issued no shares of its common stock. As of May 14, 2020, the Company had outstanding 457,578 shares of common stock. On October 25, 2019, the Company closed voting by written consent as detailed in its Proxy Statement on form 14A, filed September 5, 2019 pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended (“Proxy Statement”). The Proxy Statement disclosed actions for which the Company was soliciting written consent, including consent to effect a reverse stock split of the Company’s issued and outstanding, but not authorized, common stock (the “Reverse Split”) at a ratio of 1,000-to-1. The Company’s shareholders approved the Reverse Split. The implementation of the shareholder approval is subject to approval by the Financial Industry Regulatory Authority (“FINRA”). As of May 14, 2020, the Company had not yet received the approval from FINRA. The financial statements accompanying this Form 10-K are presented on the basis of the implementation of the shareholder consent. On February 2, 2020, the Company amended its by-laws to increase its authorized common stock to 750,000,000 shares. On February 27, 2020, the Company approved and entered into a license agreement (the “License Agreement”) with Forte Biotechnology International Corp. (“Forte”). Under the License Agreement, the Company granted Forte an exclusive license to develop and commercialize pharmaceutical products consisting of Lodonal and MENK for use in veterinary applications for all indications world-wide. As consideration for the license, Forte has agreed to make certain payments to the Company as follows: ● Initial License Fee of $3,740,746, payable by the assumption by Forte by no later than May 16, 2020 of certain Notes Payable issued by the Company in that amount. ● Development Milestone Payments. Upon the occurrence of the below-described events, the following one-time, non-creditable, non-refundable milestone payments: Event Milestone Payment* Successful MUMS Designation $ 100,000 Successful Conditional Approval $ 100,000 ● Commercial Milestone Payments. Upon reaching the mutually agreed aggregate net sales, Forte will pay one-time, non-creditable, non-refundable milestone payments to be negotiated and addressed in a separate Amendment later. ● Royalties. Forte will pay, during the royalty term (generally 15 years from the first sale of a product in a country), royalties on annual net sales as follows: Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 % On March 30, 2020, the Company issued a Convertible Promissory Note (the “Note”) to Redstart Holdings Corp. (“Redstart”) in the principal amount of $53,000. The Note matures on March 30, 2021, and bears interest at the rate of 12% per annum. Any amount of the Note not repaid at maturity, will bear interest at the rate of 22% per annum. Redstart will have the right, at any time during the period beginning 180 days following the date of the Note and ending the later of the maturity date or the date of payment of the default amount, to convert all or any part of the outstanding and unpaid amount of the Note into shares of the Company’s common stock. The conversion price will be equal to 61% multiplied by the lowest trading price for the common stock during the 20 trading day period ending on the latest complete trading day prior to the conversion date. The Company has agreed to reserve from its authorized and unissued common stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of common stock upon the full conversion of the Note. The Company is also required at all times to have authorized and reserved six times the number of shares that would be issuable upon full conversion of the Note (initially 96,539,162 shares). On April 29, 2020, Mr. Michael Handley, director, president and CEO of the Company tendered his resignation in a letter to the Company’s Board, which was formally accepted on April 30, 2020. Mr. Handley will remain in the leadership of the Company’s non-public affiliates, Cytocom, Inc. and Forte Biotechnology Intl. Corp. The Company’s Board appointed director Kevin J. Phelps as interim president and CEO. On May 4, 2020, Director Clifford Selsky submitted his resignation to the Board. Dr. Selsky had been unable to participate in recent Board meetings and anticipates this to continue during the current corporate and leadership transition, due to the demands of his pediatric medical practice during the COVID-19 pandemic. On May 13, 2020, the Company and Cytocom entered into Amendment to The Second Amendment to The License Agreement (“Third Amendment”) to their Second Amendment to The License Agreement that is effective December 31, 2018. The Third Amendment made changes to the lists of liabilities that were assigned by the Company to Cytocom on the effective date. Simultaneously with the Third Amendment, the companies signed a PRC Amendment to The Second Amendment to The License Agreement, in which they confirmed that the term “the Republic of China” in the Second Amendment means the People’s Republic of China and not The Republic of China, also known as Taiwan. On June 15, 2020, the Company issued a Convertible Promissory Note (the “Note”) to Geneva Roth Remark Holdings, Inc., (“Geneva Roth”) in the principal amount of $38,000. The Note matures on June 15, 2021, and bears interest at the rate of 12% per annum. Any amount of the Note not repaid at maturity, will bear interest at the rate of 22% per annum. Geneva Roth will have the right, at any time during the period beginning 180 days following the date of the Note and ending the later of the maturity date or the date of payment of the default amount, to convert all or any part of the outstanding and unpaid amount of the Note into shares of the Company’s common stock. The conversion price will be equal to 61% multiplied by the lowest trading price for the common stock during the 20 trading day period ending on the latest complete trading day prior to the conversion date. The Company has agreed to reserve from its authorized and unissued common stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of common stock upon the full conversion of the Note. The Company is also required at all times to have authorized and reserved six times the number of shares that would be issuable upon full conversion of the Note (initially 30,636,925 shares). On July 22, 2020, director Kevin J. Phelps, interim president and CEO of the Company entered into a three-year executive employment agreement with the Company to serve as president and CEO. This agreement was formally approved by the Company’s Board as of July 24, 2020 with Mr. Phelps abstaining. While fully effective, the parties may expand and restate the Agreement within thirty days. On August 13, 2020, the Company issued a Convertible Promissory Note (the “Note”) to Geneva Roth Remark Holdings, Inc., (“Geneva Roth”) in the principal amount of $53,000. The Note matures on August 13, 2021, and bears interest at the rate of 12% per annum. Any amount of the Note not repaid at maturity, will bear interest at the rate of 22% per annum. Geneva Roth will have the right, at any time during the period beginning 180 days following the date of the Note and ending the later of the maturity date or the date of payment of the default amount, to convert all or any part of the outstanding and unpaid amount of the Note into shares of the Company’s common stock. The conversion price will be equal to 61% multiplied by the lowest trading price for the common stock during the 20 trading day period ending on the latest complete trading day prior to the conversion date. The Company has agreed to reserve from its authorized and unissued common stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of common stock upon the full conversion of the Note. The Company is also required at all times to have authorized and reserved six times the number of shares that would be issuable upon full conversion of the Note (initially 35,463,365 shares). On August 16, 2020, the Company and Cytocom, Inc. (“Cytocom”) closed on an agreement for the Company to sublicense Lodonal (“LDN”) and Methionine Enkephalin (“MENK”) for emerging markets. Under the terms of the agreement, Cytocom will assume approximately $5,200,000 in the Company’s note, loan and other financial obligations. Pursuant to the sublicensing agreement, Cytocom will assume the following approximate obligations of the Company: $1,051,000 in accrued liabilities and accounts payable, $3,038,000 in notes and loans payable, and $1,111,000 in obligations owed to former Immune employees.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2018. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
Non-Controlling Interest in Consolidated Subsidiaries	Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At December 31, 2019, the Company’s equity interest in Cytocom stood at 14.6% of Cytocom’s common stock issued and outstanding. The Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. As the balance of the Company’s investment in Cytocom has been $0 since December 31, 2018, no losses have been recognized during the year ended December 31, 2019.
Revenue Recognition	Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. Sales of Lodonal TM
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. At December 31, 2019 we had no leases to which the standard applies. Accordingly, the standard had no material impact on our results of operations in 2019.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2019, the Company has no cash balances in excess of insured limits.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments”
Derivative Financial Instruments	Derivative Financial Instruments FASB ASC 815, Fair Value Measurements
Inventory	Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense. Inventory as of December 31, 2019 was valued at $0, a decrease of $82,801 or 100% from the inventory balance at the end of 2018, as the inventory was deemed obsolete during June of 2019, and written off as a component of selling, general and administrative expense.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the years ended December 31, 2019 and December 31, 2018 was $2,074 and $1,733, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2019 and 2018, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2019, and 2018, the Company has not accrued any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees
Net Loss Per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The Company’s potential dilutive securities, which include stock and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2019 2018 Common Stock Purchase Warrants 4,187,579 281,251 Convertible Debt 168,160 180,603
Recent Accounting Standards	Recent Accounting Standards During the year ended December 31, 2019, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Antidilutive Securities	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2019 2018 Common Stock Purchase Warrants 4,187,579 281,251 Convertible Debt 168,160 180,603

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Fixed Assets:
Schedule of Fixed Assets	December 31, 2019 2018 Fixed assets: Computer equipment $ 13,213 $ 13,213 Less accumulated depreciation (12,522 ) (10,447 ) Fixed assets, net $ 691 $ 2,766

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses and other liabilities consist of the following: December 31, 2019 2018 Accrued payroll to officers and others 3,610,810 2,010,570 Accrued interest and penalties - notes payable 899,904 877,571 Estimated legal settlements 136,057 136,057 Other accrued liabilities 48,217 15,512 Total accrued expenses and other liabilities $ 4,694,988 $ 3,039,710

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consist of the following: December 31, 2019 December 31, 2018 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. The note earned interest at a rate of 18% per annum. The Company settled this note with a new note in the same amount on October 1, 2019. $ - $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at December 31, 2019, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $675,994 earn interest at rates between 2% and 10% per annum. One loan, in the amount of $100,000, interest was payable in a fixed amount not tied to a specific interest rate. However, this note was extinguished and reassigned to a related party during the year ended December 31, 2019. The Company was unable to repay the remaining notes at maturity and at December 31, 2019 these notes were in default. 625,994 725,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at December 31, 2019 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at December 31, 2019 the notes were in default. 206,000 206,000 Promissory notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As December 31, 2019, the notes were in default. 1,354,000 1,354,000 Promissory notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and September 30, 2018. At December 31, 2019, the notes were in default. 500,000 500,000 Promissory notes issued January 25, 2017. The lenders earn interest at 7% per month. The notes matured on July 5, 2017, and at December 31, 2019 the notes were in default. The Company settled this note with a new note in the same amount on October 1, 2019. - 50,000 Promissory notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At December 31, 2019, the notes were in default. 300,000 300,000 Promissory notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At December 31, 2019, the notes were in default. 191,800 191,800 Promissory note for $425,000 issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at December 31, 2019 had increased to $454,032. $49,943 of accrued interest owed on the note has been converted to stock. The Company has accrued a $798,126 derivative liability for the remaining conversion right. 454,032 455,122 Promissory notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At December 31, 2019, the notes were in default. 105,500 105,500 Promissory notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At December 31, 2019, the notes were in default. 47,975 47,975 Promissory notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000 and 20,000 shares with an exercise price of $0.5. At December 31, 2019 the notes were in default 125,000 125,000 Promissory notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000 and 5,000 shares with an exercise price of $5. At December 31, 2019 the notes were in default 65,000 65,000 Promissory notes aggregating $198,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600 and 5,000 shares with an exercise price of $5. At December 31, 2019, the notes were in default. 198,000 193,000 Promissory notes aggregating $533,855 issued in the fourth quarter of 2018. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200 and 39,500 shares with an exercise price of $5 to $40. At December 31, 2019, the note was in default. 533,855 533,855 Promissory note for $23,000 issued in the first quarter of 2019. The note accrues interest at 2% per annum and matures during July 2019. The note includes warrants for 4,600 shares with an exercise price of $5. At December 31, 2019, the note was in default. 23,000 - Promissory note for $231,478 issued in the first quarter of 2019. The note accrues interest at 6% per annum and matured in February 2020. As of the date of this filing, this note is in default. 231,478 - Promissory notes aggregating $50,000 issued in the second quarter of 2019. The notes accrue interest at 2% per annum and mature between July and September 2019. These notes include warrants for 10,000 shares with an exercise price of $5. At December 31, 2019, the notes were in default. 50,000 - Promissory note in the amount of $150,000 issued on October 1, 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15% per annum, with $1,875 due in monthly interest payments. and matures on April 30, 2021. 150,000 - Less: Original issue discount on notes payable and warrants issued with notes. - (149,256 ) Total $ 5,545,371 $ 5,187,727

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions	The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumptions during the year ended December 31, 2019: Year End Volatility 165.62 % Risk-free interest rate 1.96 % Expected dividends - % Expected term 1 year
Schedule of Valuation of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of December 31, 2019: Fair Value Measurements as of Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability - - 798,126 Total liabilities $ - $ - $ 798,126
Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities	The following table sets forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Beginning balance $ 786,706 Settlement of liability - Change in fair value 46,745 Partial settlements of liability (35,325 ) Ending balance $ 798,126

Capital Structure - Common St_2

Capital Structure - Common Stock and Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants at December 31, 2019: Number of Exercise Per Share Weighted Warrants as of December 31, 2017 84,287 $ 10-15,000 $ 330 Issued in 2018 4,122,833 $ 10-3,740 $ 110 Expired and forfeited in 2018 6,500 $ 15,000 $ 1,450 Exercised in 2018 - $ - $ - Warrants as of December 31, 2018 4,200,620 $ 0.05-3,740 $ 90 Issued in 2019 14,600 $ 5 $ 5 Expired and forfeited in 2019 27,641 $ 50-3,740 $ 536 Exercised in 2019 - $ - $ - Warrants as of December 31, 2019 4,187,579 $ 0.05-500 $ 2.43
Summary of Outstanding Warrants	Summary of outstanding warrants as of December 31, 2019: Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2020 300 $ 500 0.50 Fourth Quarter 2020 1,000 $ 200 1.00 First Quarter 2021 12,600 $ 200 1.25 Second Quarter 2021 5,812 $ 14-200 1.50 Third Quarter 2021 5,167 $ 30-200 1.75 Fourth Quarter 2021 300 $ 100 2.00 First Quarter 2022 150 $ 200 2.25 Second Quarter 2022 1,750 $ 150 2.50 Third Quarter 2022 2,650 $ 50-100 2.75 Fourth Quarter 2022 9,811 $ 80-290 3.00 First Quarter 2023 9,000 $ 5-40 3.25 Second Quarter 2023 15,000 $ 5-200 3.50 Third Quarter 2023 76,700 $ 5-100 3.75 Fourth Quarter 2023 3,970,743 $ 0.05-20 4.00 First Quarter 2024 36,600 $ 5 4.25 Second Quarter 2024 8,000 $ 5 4.50 Third Quarter 2028 3,000 $ 70 8.75 Second Quarter 2032 28,995 $ 10-70 12.50 4,187,579 $ 0.05-500

Income Taxes - Results of Ope_2

Income Taxes - Results of Operations (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets: 2019 2018 Net operating losses $ 20,346,000 $ 19,671,000 Stock based compensation 39,284,000 39,256,000 Amortization, depreciation, and impairment 4,178,000 4,178,000 Capitalization of start-up costs for tax purposes 1,145,000 1,145,000 Gain/(loss) on conversion of debt 713,000 713,000 Total deferred tax assets 65,666,000 64,963,000 Valuation allowance (65,666,000 ) (64,963,000 ) Total deferred tax assets, net $ - $ -
Schedule of Income Taxes Net Operating Loss	As of December 31, 2019, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $97,069,000, which will expire in 2032-2037. 2019 2018 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ 713,000 21 % $ 1,811,000 21 % Permanent differences 10,000 (2,000 ) Increase (decrease) in valuation allowance (703,000 ) (21) % (1,809,000 ) (21) % Income tax expense (benefit) at Company’s effective tax rate $ - - % $ - - %

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Schedule of Milestone Payment	Event Milestone Payment* Successful MUMS Designation $ 100,000 Successful Conditional Approval $ 100,000
Schedule of Royalty Rate	Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 %

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)	Jun. 04, 2018	May 01, 2018	Dec. 08, 2014	Dec. 31, 2014	Dec. 31, 2019	Dec. 31, 2018	Apr. 08, 2019	Dec. 31, 2017
Net loss attributable to common shareholders					$ (3,396,658)	$ (8,175,228)
Cash and cash equivalents used in operating activities					(934)	(1,369,503)
Stockholder's deficit					$ (13,688,621)	$ (11,250,638)		$ (11,103,386)
Cytocom Inc., [Member]
Ownership percentage					14.60%
Licensing Agreement [Member]
Ownership percentage							15.57%
Cytocom Inc., [Member]
Royalty percentage				5.00%
Cytocom Inc., [Member] | Original Agreement [Member]
Number of common stock issued			140,100,000
Ownership percentage			55.30%
Cytocom Inc., [Member] | Restated Agreement [Member] | Minimum [Member]
Royalty percentage		1.00%
Cytocom Inc., [Member] | Restated Agreement [Member] | Maximum [Member]
Royalty percentage		5.00%
Cytocom Inc., [Member] | Stock Purchase Agreement [Member]
Amount of debt converted into common stock	$ 4,000,000
Percentage of common stock issued in exchange of debt	10.00%
Cytocom Inc., [Member] | Shareholders [Member]
Number of common stock issued			113,242,522

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Jun. 04, 2018USD ($)	Dec. 31, 2019USD ($)Segment	Dec. 31, 2018USD ($)
Maximum of annual gross revenue			$ 1,000,000,000
Federal deposit insurance corporation value		$ 250,000
Number of operating segment | Segment		1
Inventory			82,801
Decrease in inventory		$ 82,801
Percentage of decrease in inventory		100.00%
Depreciation expense		$ 2,074	1,734
Accrued interest or penalties related to uncertain tax positions
Minimum [Member]
Property and equipment useful lives		3 years
Maximum [Member]
Property and equipment useful lives		5 years
Cytocom Inc., [Member]
Percentage of equity ownership		14.60%
Cytocom Inc., [Member]
Investment			$ 0
Cytocom Inc., [Member] | Stock Purchase Agreement [Member]
Amount of debt converted into common stock	$ 4,000,000
Percentage of common stock issued in exchange of debt	10.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Common Stock Purchase Warrants [Member]
Potentially dilutive securities	4,187,579	281,251
Convertible Debt [Member]
Potentially dilutive securities	168,160	180,603

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative)	12 Months Ended
	Dec. 31, 2019
Minimum [Member]
Property and equipment useful lives	3 years
Maximum [Member]
Property and equipment useful lives	5 years

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Fixed Assets:
Computer equipment	$ 13,213	$ 13,213
Less accumulated depreciation	(12,522)	(10,447)
Fixed assets, net	$ 691	$ 2,766

Investments_ Deconsolidation _2

Investments: Deconsolidation of Cytocom (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	May 01, 2018
Due to related party		$ 262,645
Recover the net payable balance outstanding	382,308
Cato Research Ltd [Member]
Due to related party	409,390
Penn State University [Member]
Due to related party	377,774
Cytocom Inc., [Member]
Equity method investments			$ 1,189
Loss on investment	$ 0

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued payroll to officers and others	$ 3,610,810	$ 2,010,570
Accrued interest and penalties - notes payable	899,904	877,571
Estimated legal settlements	136,057	136,057
Other accrued liabilities	48,217	15,512
Total accrued expenses and other liabilities	$ 4,694,988	$ 3,039,710

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accrued unpaid interest and default penalties	$ 899,904	$ 877,571
Issuance of common stock for conversion of debt	62,435	$ 671,587
Settlement debt	100,000
Accrued interest and penalties	$ 596,850
Promissory Notes [Member]
Issuance of common stock for conversion of debt, shares	18,255	30,351
Issuance of common stock for conversion of debt	$ 78,500	$ 318,182
Settlement of promissory notes	$ 62,435	$ 175,000

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Oct. 31, 2017
Total	$ 5,545,371	$ 5,187,727
Less: Original issue discounts on notes payable and warrants issued with notes		(149,256)
Notes Payable One [Member]
Total		100,000
Notes Payable Two [Member]
Total	286,000	286,000
Notes Payable Three [Member]
Total	625,994	725,994
Notes Payable Four [Member]
Total	97,737	97,737
Notes Payable Five [Member]
Total	206,000	206,000
Notes Payable Six [Member]
Total	1,354,000	1,354,000
Notes Payable Seven [Member]
Total	500,000	500,000
Notes Payable Eight [Member]
Total		50,000
Notes Payable Nine [Member]
Total	300,000	300,000
Notes Payable Ten [Member]
Total	191,800	191,800
Notes Payable Eleven [Member]
Total	454,032	455,122
Less: Original issue discounts on notes payable and warrants issued with notes			$ (70,000)
Notes Payable Twelve [Member]
Total	105,500	105,500
Notes Payable Thirteen [Member]
Total	47,975	47,975
Notes Payable Fourteen [Member]
Total	125,000	125,000
Notes Payable Fifteen [Member]
Total	65,000	65,000
Notes Payable Sixteen [Member]
Total	198,000	193,000
Notes Payable Seventeen [Member]
Total	533,855	533,855
Notes Payable Eighteen [Member]
Total	23,000
Notes Payable Nineteen [Member]
Total	231,478
Notes Payable Twenty [Member]
Total	50,000
Notes Payable Twenty One [Member]
Total	$ 150,000

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)

Oct. 02, 2019USD ($)

Jan. 25, 2017

Nov. 03, 2015

Jun. 30, 2019USD ($)$ / sharesshares

Mar. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Sep. 30, 2018USD ($)$ / sharesshares

Jun. 30, 2018USD ($)$ / sharesshares

Mar. 31, 2018USD ($)$ / sharesshares

Sep. 30, 2017USD ($)

Jun. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)Installments

Dec. 31, 2016USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2017USD ($)

Oct. 31, 2017USD ($)

Original issuance discount

$ 149,256

Notes Payable Two [Member]

Percentage of interest rate per annum

10.00%

Number of installments, months | Installments

36

Notes Payable Two [Member] | Maximum [Member]

Maximum amount raise in debt

$ 2,000,000

Notes Payable Four [Member]

Note matures date

Nov. 3, 2016

Percentage of interest rate per annum

10.00%

Notes Payable Five [Member] | Lenders [Member]

Note matures date

Dec. 31, 2017

Percentage of interest rate per annum

2.00%

2.00%

2.00%

2.00%

Notes Payable Six [Member]

Percentage of interest rate per annum

2.00%

2.00%

2.00%

2.00%

Debt instrument maturity date description

November 1, 2017 and December 31, 2017

Notes aggregating default amount

$ 1,350,000

$ 1,350,000

$ 1,350,000

$ 1,350,000

Notes Payable Seven [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

January 12, 2018 and September 30, 2018

Notes aggregating default amount

$ 500,000

Notes Payable Nine [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

April 3, 2018 and May 31, 2018

Notes aggregating default amount

$ 300,000

Notes Payable Ten [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

June 16, 2018 and December 31, 2018

Notes aggregating default amount

$ 191,800

Notes Payable Eleven [Member]

Maximum amount raise in debt

454,032

Accrued interest

49,943

Notes aggregating default amount

$ 425,000

Original issuance discount

$ 70,000

Derivative liability

$ 798,126

Notes Payable Twelve [Member]

Percentage of interest rate per annum

2.00%

Notes aggregating default amount

$ 105,500

Notes Payable Thirteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

May 2018 and January 2019

Notes aggregating default amount

$ 47,975

Notes Payable Fourteen [Member]

Debt instrument maturity date description

April 2018 and June 2018

Notes aggregating default amount

$ 125,000

Warrant exercise price per share | $ / shares

$ 0.5

Notes Payable Fourteen [Member] | Maximum [Member]

Percentage of interest rate per annum

12.00%

Number of warrants | shares

20,000

Notes Payable Fourteen [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

Number of warrants | shares

5,000

Notes Payable Fifteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2018 and October 2018

Notes aggregating default amount

$ 65,000

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Fifteen [Member] | Maximum [Member]

Number of warrants | shares

5,000

Notes Payable Fifteen [Member] | Minimum [Member]

Number of warrants | shares

1,000

Notes Payable Sixteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

November 2018 and January 2019

Notes aggregating default amount

$ 198,000

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Sixteen [Member] | Maximum [Member]

Number of warrants | shares

5,000

Notes Payable Sixteen [Member] | Minimum [Member]

Number of warrants | shares

600

Notes Payable Seventeen [Member]

Debt instrument maturity date description

February 2019 and December 2019

Notes aggregating default amount

$ 533,855

Notes Payable Seventeen [Member] | Maximum [Member]

Percentage of interest rate per annum

3.50%

Number of warrants | shares

39,500

Warrant exercise price per share | $ / shares

$ 40

Notes Payable Seventeen [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

Number of warrants | shares

200

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Eighteen [Member]

Note matures date

Jul. 31, 2019

Percentage of interest rate per annum

2.00%

Notes aggregating default amount

$ 23,000

Number of warrants | shares

4,600

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Nineteen [Member]

Note matures date

Feb. 29, 2020

Percentage of interest rate per annum

6.00%

Notes aggregating default amount

$ 231,478

Notes Payable Twenty [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July and September 2019

Notes aggregating default amount

$ 50,000

Number of warrants | shares

10,000

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Twenty One [Member]

Percentage of interest rate per annum

15.00%

Debt instrument maturity date description

Matures on April 30, 2021.

Notes aggregating default amount

$ 150,000

Debt instrument, periodic payment, principal

$ 1,875

Ira Gaines [Member] | Notes Payable One [Member]

Note matures date

Dec. 1, 2017

Percentage of interest rate per annum

18.00%

Lenders [Member] | Notes Payable Three [Member]

Debt instrument maturity date description

June 14, 2015 and December 1, 2017

Aggregating loan

675,994

675,994

$ 675,994

$ 675,994

Accrued interest

$ 100,000

$ 100,000

$ 100,000

$ 100,000

Lenders [Member] | Notes Payable Three [Member] | Maximum [Member]

Percentage of interest rate per annum

10.00%

10.00%

10.00%

10.00%

Lenders [Member] | Notes Payable Three [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

2.00%

2.00%

2.00%

Lenders [Member] | Notes Payable Eight [Member]

Note matures date

Jul. 5, 2017

Percentage of interest rate per annum

7.00%

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities	$ 798,126	$ 786,706

Derivative Liability - Schedule

Derivative Liability - Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions (Details) - Black-Scholes Option Pricing Model [Member]	12 Months Ended
	Dec. 31, 2019
Volatility [Member]
Fair value assumptions, measurement input, percentages	1.6562
Risk-Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	0.0196
Expected Dividends [Member]
Fair value assumptions, measurement input, percentages	0
Expected Term [Member]
Fair value assumptions, measurement input, term	1 year

Derivative Liability - Schedu_2

Derivative Liability - Schedule of Valuation of Financial Instruments (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Total liabilities	$ 13,694,437	$ 11,342,264
Level 1 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 2 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 3 [Member]
Total assets
Conversion option derivative liability	798,126
Total liabilities	$ 798,126

Derivative Liability - Schedu_3

Derivative Liability - Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities (Details) - Level 3 [Member]	12 Months Ended
	Dec. 31, 2019USD ($)
Derivative liabilities beginning balance	$ 786,706
Settlement of liability
Change in fair value	46,745
Partial settlements of liability	(35,325)
Derivative liabilities ending balance	$ 798,126

Capital Structure - Common St_3

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Common stock, shares authorized	500,000,000	500,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares outstanding	457,578	434,323
Warrant [Member]
Number of warrants issued during period	14,600
Warrant expiration date description	Exercisable into one share of common stock of the Company for each warrant at prices of $5.00 per share. The warrants expire between March and May of 2024.
Warrant exercise price	$ 5

Capital Structure - Common St_4

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Shares Warrants, Beginning balance	4,200,620	84,287
Number of Shares Warrants, Issued	14,600	4,122,833
Number of Shares Warrants, Expired and forfeited	27,641	6,500
Number of Shares Warrants, Exercised
Number of Shares Warrants, Ending balance	4,187,579	4,200,620
Exercise Price, Issued	$ 5
Exercise Price, Expired and forfeited		$ 15,000
Exercise Price, Exercised
Weighted average price, Beginning balance	90	330
Weighted average price, Issued	5	110
Weighted average price, Expired and forfeited	536	1,450
Weighted average price, Exercised
Weighted average price, Ending balance	2.43	90
Maximum [Member]
Exercise Price, Beginning balance	0.05	10
Exercise Price, Issued		10
Exercise Price, Expired and forfeited	50
Exercise Price, Ending balance	0.05	0.05
Minimum [Member]
Exercise Price, Beginning balance	3,740	15,000
Exercise Price, Issued		3,740
Exercise Price, Expired and forfeited	3,740
Exercise Price, Ending balance	$ 500	$ 3,740

Capital Structure - Common St_5

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of Shares | shares	4,187,579
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 500
Second Quarter 2020 [Member]
Number of Shares | shares	300
Exercise Price Upper Limit	$ 500
Remaining Life (years)	6 months
Fourth Quarter 2020 [Member]
Number of Shares | shares	1,000
Exercise Price Upper Limit	$ 200
Remaining Life (years)	1 year
First Quarter 2021 [Member]
Number of Shares | shares	12,600
Exercise Price Upper Limit	$ 200
Remaining Life (years)	1 year 2 months 30 days
Second Quarter 2021 [Member]
Number of Shares | shares	5,812
Exercise Price Lower Limit	$ 14
Exercise Price Upper Limit	$ 200
Remaining Life (years)	1 year 6 months
Third Quarter 2021 [Member]
Number of Shares | shares	5,167
Exercise Price Lower Limit	$ 30
Exercise Price Upper Limit	$ 200
Remaining Life (years)	1 year 9 months
Fourth Quarter 2021 [Member]
Number of Shares | shares	300
Exercise Price Upper Limit	$ 100
Remaining Life (years)	2 years
First Quarter 2022 [Member]
Number of Shares | shares	150
Exercise Price Upper Limit	$ 200
Remaining Life (years)	2 years 2 months 30 days
Second Quarter 2022 [Member]
Number of Shares | shares	1,750
Exercise Price Upper Limit	$ 150
Remaining Life (years)	2 years 6 months
Third Quarter 2022 [Member]
Number of Shares | shares	2,650
Exercise Price Lower Limit	$ 50
Exercise Price Upper Limit	$ 100
Remaining Life (years)	2 years 9 months
Fourth Quarter 2022 [Member]
Number of Shares | shares	9,811
Exercise Price Lower Limit	$ 80
Exercise Price Upper Limit	$ 290
Remaining Life (years)	3 years
First Quarter 2023 [Member]
Number of Shares | shares	9,000
Exercise Price Lower Limit	$ 5
Exercise Price Upper Limit	$ 40
Remaining Life (years)	3 years 2 months 30 days
Second Quarter 2023 [Member]
Number of Shares | shares	15,000
Exercise Price Lower Limit	$ 5
Exercise Price Upper Limit	$ 200
Remaining Life (years)	3 years 6 months
Third Quarter 2023 [Member]
Number of Shares | shares	76,700
Exercise Price Lower Limit	$ 5
Exercise Price Upper Limit	$ 100
Remaining Life (years)	3 years 9 months
Fourth Quarter 2023 [Member]
Number of Shares | shares	3,970,743
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 20
Remaining Life (years)	4 years
First Quarter 2024 [Member]
Number of Shares | shares	36,600
Exercise Price Upper Limit	$ 5
Remaining Life (years)	4 years 2 months 30 days
Second Quarter 2024 [Member]
Number of Shares | shares	8,000
Exercise Price Upper Limit	$ 5
Remaining Life (years)	4 years 6 months
Third Quarter 2028 [Member]
Number of Shares | shares	3,000
Exercise Price Upper Limit	$ 70
Remaining Life (years)	8 years 9 months
Second Quarter 2032 [Member]
Number of Shares | shares	28,995
Exercise Price Lower Limit	$ 10
Exercise Price Upper Limit	$ 70
Remaining Life (years)	12 years 6 months

Stock Compensation (Details Nar

Stock Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization of prepaid services	$ 0	$ 226,667
Minimum [Member]
Consulting fees amortized period	12 months
Maximum [Member]
Consulting fees amortized period	24 months
Consulting Fees [Member]
Number of common stock issued for services	0	16,999

Income Taxes - Results of Ope_3

Income Taxes - Results of Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income tax examination, description	The impact of U.S. Tax Reform primarily represents the Company’s estimates of revaluing the Company’s U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%, effective for the 2018 tax year.
Percentage of statutory income tax rate	21.00%	21.00%
Lower corporate tax rate	21.00%
Operating loss carryforwards	$ 97,069,000
Operating loss carryforwards expire term	Expire in 2032-2037

Income Taxes - Results of Ope_4

Income Taxes - Results of Operations - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net operating losses	$ 20,346,000	$ 19,671,000
Stock based compensation	39,284,000	39,256,000
Amortization, depreciation, and impairment	4,178,000	4,178,000
Capitalization of start-up costs for tax purposes	1,145,000	1,145,000
Gain/(loss) on conversion of debt	713,000	713,000
Total deferred tax assets	65,666,000	64,963,000
Valuation allowance	(65,666,000)	(64,963,000)
Total deferred tax assets, net

Income Taxes - Results of Ope_5

Income Taxes - Results of Operations - Schedule of Income Taxes Net Operating Loss (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Benefits for income tax at federal statutory rate	$ 713,000	$ 1,811,000
Permanent differences	10,000	(2,000)
Increase (decrease) in valuation allowance	(703,000)	(1,809,000)
Income tax expense (benefit) at Company's effective tax rate
Benefits for income tax at federal statutory rate, percent	21.00%	21.00%
Permanent differences, percent	0.00%	0.00%
Increase (decrease) in valuation allowance, percent	(21.00%)	(21.00%)
Income tax expense (benefit) at Company’s effective tax rate, percent	0.00%	0.00%

Licenses and Supply Agreements

Licenses and Supply Agreements (Details Narrative) - Cytocom Inc., [Member]	May 01, 2018	Dec. 31, 2014
Royalty percentage		5.00%
Maximum [Member] | Restated Agreement [Member]
Royalty percentage	5.00%
Minimum [Member] | Restated Agreement [Member]
Royalty percentage	1.00%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2013	Dec. 31, 2019	Dec. 31, 2018
Rental expense		$ 12,661	$ 11,775
AHAR Pharma [Member]
Distribution agreement, description	The Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal product to cover AHAR Pharma's first-year purchase commitment.

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Due to related party		$ 262,645
Brewer and Associates Consulting LLC [Member]
Notes payable	36,000	36,000
Raster Investments, Inc [Member]
Notes payable	40,000
Global Reverb, Corp [Member]
Notes payable	$ 23,000
Interest rate	2.00%
Two Notes Payable [Member] | Raster Investments, Inc [Member]
Notes payable		210,000
Michael Handley [Member]
Officers Compensation	$ 120,000
Unpaid cash compensation	120,000
Noreen Griffin [Member]
Officers Compensation	377,960	355,594
Unpaid cash compensation	1,962,464	1,584,504
Due to related party	48,217
Robert Wilson [Member]
Officers Compensation	120,000	120,000
Unpaid cash compensation	190,000	70,000
Cash compensation received		$ 70,000
Number of stock options issued		500,000
Number of stock options issued value		$ 24,998
Kelly O'Brien Wilson [Member]
Officers Compensation	163,390	163,390
Unpaid cash compensation	258,701	95,311
Cash compensation received		$ 136,158
Number of stock options issued		1,200,000
Number of stock options issued value		$ 59,995
Peter Aronstam [Member]
Officers Compensation	60,000	60,000
Unpaid cash compensation	71,000	36,000
Clifford Selsky [Member]
Officers Compensation	5,000
Unpaid cash compensation	230,000	60,000
Kevin Phelps [Member]
Officers Compensation	5,000
Unpaid cash compensation	65,000	10,000
Michael Sander [Member]
Officers Compensation	5,000
Unpaid cash compensation	10,000	$ 0
Roscoe Moore [Member]
Officers Compensation	1,500
Number of stock options issued		1,875,000
Number of stock options issued value		$ 37,500
Accrued compensation	95,250	24,500
Notes payable	25,000
Edward Teraskiewicz [Member]
Officers Compensation	5,000
Unpaid cash compensation	$ 114,643	45,000
Edward Teraskiewicz [Member] | Two Notes Payable [Member] | Raster Investments, Inc [Member]
Notes payable		150,000
Interest rate	2.00%
Repayment of other liabilities		60,000
Jack Brewer [Member]
Officers Compensation	$ 5,000
Unpaid cash compensation	$ 60,000	$ 20,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Aug. 13, 2020USD ($)TradingDaysshares	Jun. 15, 2020USD ($)TradingDaysshares	Mar. 30, 2020USD ($)TradingDaysshares	Feb. 27, 2020USD ($)	Oct. 25, 2019	May 14, 2020shares	Aug. 16, 2020USD ($)	Feb. 02, 2020shares	Dec. 31, 2019shares	Dec. 31, 2018shares
Common stock, shares outstanding | shares									457,578	434,323
Reverse stock split, description					The Proxy Statement disclosed actions for which the Company was soliciting written consent, including consent to effect a reverse stock split of the Company’s issued and outstanding, but not authorized, common stock (the “Reverse Split”) at a ratio of 1,000-to-1.
Common stock, shares authorized | shares									500,000,000	500,000,000
Subsequent Event [Member]
Number of common stock shares issued | shares
Common stock, shares outstanding | shares						457,578
Initial license fee | $				$ 3,740,746
Royalty term				15 years
Subsequent Event [Member] | Cytocom Inc., [Member] | Sublicense Lodonal ("LDN") and Methionine Enkephalin ("MENK") [Member]
Note, loan and other financial obligations | $							$ 5,200,000
Accrued liabilities and accounts payable | $							1,051,000
Notes and loans payable | $							3,038,000
Due to employees | $							$ 1,111,000
Subsequent Event [Member] | Convertible Promissory Note [Member] | Redstart Holdings Corp [Member]
Debt principal amount | $			$ 53,000
Interest rate			12.00%
Debt maturity date			Mar. 30, 2021
Debt interest on after maturity			22.00%
Debt conversion price percentage			0.61
Debt lowest trading price | TradingDays			20
Issuance of common stock for conversion of debt | shares			96,539,162
Subsequent Event [Member] | Convertible Promissory Note [Member] | Geneva Roth Remark Holdings, Inc [Member]
Debt principal amount | $	$ 53,000	$ 38,000
Interest rate	12.00%	12.00%
Debt maturity date	Aug. 13, 2021	Jun. 15, 2021
Debt interest on after maturity	22.00%	22.00%
Debt conversion price percentage	0.61	0.61
Debt lowest trading price | TradingDays	20	20
Issuance of common stock for conversion of debt | shares	35,463,365	30,636,925
Subsequent Event [Member] | Maximum [Member]
Common stock, shares authorized | shares								750,000,000

Subsequent Events - Schedule of

Subsequent Events - Schedule of Milestone Payment (Details) - Subsequent Event [Member]	Feb. 27, 2020USD ($)
Successful MUMS Designation [Member]
Milestone Payment	$ 100,000
Successful Conditional Approval [Member]
Milestone Payment	$ 100,000

Subsequent Events - Schedule _2

Subsequent Events - Schedule of Royalty Rate (Details) - Subsequent Event [Member]	Feb. 27, 2020
Less than $500,000,000 [Member]
Royalty Rate	2.00%
500,000,000 to Less than $1,000,000,000 [Member]
Royalty Rate	4.00%
Greater than $1,000,000,000 [Member]
Royalty Rate	6.00%